Current Report Filing (8-k)
September 05 2019 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
September 3, 2019
INTEC PHARMA LTD.
(Exact name of registrant as specified
in its charter)
Israel
|
|
001-37521
|
|
N/A
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
12 Hartom St.
Har Hotzvim
|
|
|
Jerusalem, Israel
|
|
9777512
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
+ 972-2-586-4657
|
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
Ordinary Shares, no, par value
|
|
NTEC
|
|
Nasdaq Capital Market
|
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer
of Listing
On
September 3, 2019, Intec Pharma Ltd. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq
Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing
Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires
listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides
that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business
days. Based on the closing bid price of the Company’s ordinary shares for the 30 consecutive business days prior to the date
of the Notification Letter, the Company no longer meets the minimum bid price requirement. The Notification Letter has no
immediate effect on the listing or trading of the Company’s ordinary shares on the Nasdaq Capital Market and, at this time,
the ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “NTEC”.
The
Notification Letter provides that the Company has 180 calendar days, or until March 2, 2020, to regain compliance with Nasdaq Listing
Rule 5550(a)(2). To regain compliance, the bid price of the Company's ordinary shares must have a closing bid price of at least
$1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by March 2, 2020,
an additional 180 days may be granted to regain compliance, so long as the Company meets the Nasdaq Capital Market continued
listing requirements (except for the bid price requirement) and notifies Nasdaq in writing of its intention to
cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails
to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist
the Company's ordinary shares, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings
Panel.
The
Company intends to monitor the closing bid price of its ordinary shares and is considering its options to regain compliance with
the minimum bid price requirement under the Nasdaq Listing Rules.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
INTEC PHARMA LTD.
|
|
|
Date: September 5, 2019
|
By:
|
/s/ Nir Sassi
|
|
|
Nir Sassi
|
|
|
Chief Financial Officer
|
2
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2023 to Apr 2024